Related Experiment Videos
Systemic lupus erythematosus during isoniazid therapy.
R Guleria1, D Behera, S K Jindal
1Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh.
The Indian Journal of Chest Diseases & Allied Sciences
|January 1, 1990
Summary
Isoniazid therapy for tuberculosis may trigger systemic lupus erythematosus (SLE) in susceptible individuals. This case highlights a potential drug-induced autoimmune response requiring careful monitoring during treatment.
Area of Science:
- Rheumatology
- Pulmonology
- Pharmacology
Background:
- Pulmonary tuberculosis is a significant global health concern.
- Isoniazid is a primary treatment for tuberculosis.
- Systemic lupus erythematosus (SLE) is a chronic autoimmune disease.
Observation:
- A young female patient developed SLE symptoms during isoniazid treatment for tuberculosis.
- The onset of SLE coincided with the therapeutic course of isoniazid.
Findings:
- The case suggests isoniazid may induce or precipitate SLE.
- Review of literature indicates potential isoniazid-induced lupus erythematosus.
Implications:
- Clinicians should consider isoniazid as a potential cause of drug-induced lupus.
- Monitoring for SLE symptoms in patients on isoniazid therapy is crucial.
- Further research is needed to elucidate the mechanism of isoniazid-induced SLE.